Clinical trial
Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young…
NCT00053950 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00053950 |
|---|---|
| Title | Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma |
| Official title | A Phase I Study of High-dose Pyrazoloacridine (PZA) (NSC 366140) Supported With Autologous Hematopoietic Stem Cell Rescue in Children With Recurrent or Resistant Neuroblastoma (IND # 36325) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Disseminated Neuroblastoma, Recurrent Neuroblastoma |
| Intervention type | Biological, Drug, Other, Procedure |
| Interventions | pyrazoloacridine, filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis, pharmacological study |
| Enrollment | 42 |
| Start date | Dec 1, 2002 |
| Primary completion | Mar 1, 2007 |
| First posted | Feb 6, 2003 |
| Last update posted | Apr 9, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: